Analytical validity of a microRNA‐based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides

Аналитическая валидность микроРНК-ориентированного теста для диагностики неопределённых мазков тонкоигольной аспирации щитовидной железы по стандартно приготовленным цитологическим стеклам
Christopher J. VandenBussche, Fabio Pagni, Syed Zulfiqar Ali, Eti Meiri, Temima Schnitzer‐Perlman, Zdeněk Kolář, Hila Benjamin, Alexander Shtabsky, Rosetta Genomics Group, Dganit Bar, Temima Schnitzer Perlman
2016-05-25

RosettaGX Revealanalytical validationindeterminate cytology smearsmicroRNA-based assaythyroid fine-needle aspiration
BACKGROUND: The majority of thyroid nodules are diagnosed using fine-needle aspiration (FNA) biopsies. The authors recently described the clinical validation of a molecular microRNA-based assay, RosettaGX Reveal, which can diagnose thyroid nodules as benign or suspicious using a single stained FNA smear. This paper describes the analytical validation of the assay. METHODS: More than 800 FNA slides were tested, including slides stained with Romanowsky-type and Papanicolaou stains. The assay was examined for the following features: intranodule concordance, effect of stain type, minimal acceptable RNA amounts, performance on low numbers of thyroid cells, effect of time since sampling, and analytical sensitivity, specificity, and reproducibility. RESULTS: The assay can be run on FNA slides for which as little as 1% of the cells are thyroid epithelial cells or from which only 5 ng of RNA have been extracted. Samples composed entirely of blood failed quality control and were not classified. Stain type did not affect performance. All slides were stored at room temperature. However, the length of time between FNA sampling and processing did not affect assay performance. There was a high level of concordance between laboratories (96%), and the concordance for slides created from the same FNA pass was 93%. CONCLUSIONS: The microRNA-based assay was robust to various physical processing conditions and to differing sample characteristics. Given the assay's performance, robustness, and use of routinely prepared FNA slides, it has the potential to provide valuable aid for physicians in the diagnosis of thyroid nodules. Cancer Cytopathol 2016;124:711-21. © 2016 Rosetta Genomics. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
1
Reproducibility was high, with 96% interlaboratory concordance and 93% concordance among slides from the same FNA pass.
2
Romanowsky-type versus Papanicolaou staining did not affect assay performance, and delayed processing after sampling had no impact.
3
Samples composed entirely of blood failed quality control and could not be classified.
4
The RosettaGX Reveal microRNA assay accurately classified thyroid FNA samples despite varied slide preparation and sample characteristics.
5
The assay remained effective with as little as 1% thyroid epithelial cells or 5 ng of extracted RNA.

Routinely prepared thyroid fine-needle aspiration (FNA) cytology slides containing thyroid nodule samples

Analytical validity, robustness, sensitivity, specificity, reproducibility, and performance under varied sample and processing conditions of a microRNA-based assay for classifying indeterminate thyroid FNA smears

Publication Details
Publication Date
2016-05-25
Journal
Publisher
ISSN
Cited by
54
Access Type
Author Information
Authors
Christopher J. VandenBussche
Fabio Pagni
Syed Zulfiqar Ali
Eti Meiri
Temima Schnitzer‐Perlman
Zdeněk Kolář
Hila Benjamin
Alexander Shtabsky
Rosetta Genomics Group
Dganit Bar
Temima Schnitzer Perlman
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%